Home » Stocks » Immutep

Immutep Limited (IMMP)

Stock Price: $1.30 USD 0.02 (1.56%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 63.39M
Revenue (ttm) 5.27M
Net Income (ttm) -12.92M
Shares Out 38.88M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $1.30
Previous Close $1.28
Change ($) 0.02
Change (%) 1.56%
Day's Open 1.28
Day's Range 1.27 - 1.34
Day's Volume 223,338
52-Week Range 0.53 - 3.10

More Stats

Market Cap 63.39M
Enterprise Value 57.11M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 38.88M
Float 36.37M
EPS (basic) n/a
EPS (diluted) -0.40
FCF / Share 0.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 78,203
Short Ratio 0.03
Short % of Float n/a
Beta 1.17
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 12.02
PB Ratio 2.57
Revenue 5.27M
Operating Income -12.22M
Net Income -12.92M
Free Cash Flow -10.79M
Net Cash 6.29M
Net Cash / Share 0.13
Gross Margin 100.00%
Operating Margin -231.62%
Profit Margin -244.90%
FCF Margin -204.66%
ROA -22.01%
ROE -50.73%
ROIC -211.40%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.10*
(138.46% upside)
Low
2.00
Current: $1.30
High
4.20
Target: 3.10
*Average 12-month USD price target from 2 stock analysts.

Financial Performance

Financial numbers in millions AUD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue7.497.354.222.032.093.144.014.201.070.52
Revenue Growth1.85%74.19%108.07%-3.06%-33.35%-21.6%-4.69%294.16%103.58%-
Gross Profit7.497.354.222.032.093.144.014.201.070.52
Operating Income-17.35-11.69-9.35-61.47-13.93-13.33-15.11-17.27-14.13-11.01
Net Income-18.34-12.75-9.37-62.02-32.15-13.34-15.23-19.94-21.08-17.96
Shares Outstanding3,0262,080618525369320320320--
Earnings Per Share-0.01-0.01--0.03-0.02-0.03-0.05-0.06-0.13-0.12
Operating Cash Flow-15.29-7.78-8.51-11.31-7.79-14.23-16.04-19.12-12.82-6.46
Capital Expenditures-0.04-0.01-0.010.10-0.05-0.10-0.51-0.57-0.04-0.09
Free Cash Flow-15.33-7.79-8.51-11.21-7.84-14.33-16.55-19.69-12.87-6.56
Cash & Equivalents16.5723.4812.2420.886.7623.2030.0238.0455.9215.64
Total Debt7.646.655.785.031.51----0.60
Net Cash / Debt8.9316.836.4615.855.2523.2030.0238.0455.9215.04
Assets40.5447.0034.9642.5530.9825.3832.8141.6157.6418.05
Liabilities16.1513.488.437.246.292.793.574.452.542.21
Book Value24.3933.5226.5335.3224.6922.5929.2537.1655.1015.84
Numbers in millions AUD, except per-share numbers.

Company Profile

Company Details

Full Name Immutep Limited
CEO Marc Voigt

Stock Information

Ticker Symbol IMMP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMMP

Description

Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti), an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP761 for autoimmune disease. It has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreements with Merck KGaA, Darmstadt, Germany, and Pfizer Inc.; and partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.